Tevogen Bio Holdings Inc (NASDAQ:TVGN) — Market Cap & Net Worth
Market Cap & Net Worth: Tevogen Bio Holdings Inc (TVGN)
Tevogen Bio Holdings Inc (NASDAQ:TVGN) has a market capitalization of $24.40 Million ($24.40 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24403 globally and #5016 in its home market, demonstrating a -4.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tevogen Bio Holdings Inc's stock price $6.66 by its total outstanding shares 4164205 (4.16 Million). Analyse TVGN operating cash flow to see how efficiently the company converts income to cash.
Tevogen Bio Holdings Inc Market Cap History: 2024 to 2026
Tevogen Bio Holdings Inc's market capitalization history from 2024 to 2026. Data shows growth from $4.41 Million to $27.73 Million (16.14% CAGR).
Index Memberships
Tevogen Bio Holdings Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #706 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2335 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.00% | #250 of 263 |
Weight: Tevogen Bio Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tevogen Bio Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tevogen Bio Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TVGN by Market Capitalization
Companies near Tevogen Bio Holdings Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Tevogen Bio Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Tevogen Bio Holdings Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Tevogen Bio Holdings Inc's market cap moved from $4.41 Million to $ 27.73 Million, with a yearly change of 16.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $27.73 Million | +1911.48% |
| 2025 | $1.38 Million | -68.74% |
| 2024 | $4.41 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Tevogen Bio Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.40 Million USD |
| MoneyControl | $24.40 Million USD |
| MarketWatch | $24.40 Million USD |
| marketcap.company | $24.40 Million USD |
| Reuters | $24.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tevogen Bio Holdings Inc
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 pa… Read more